Hikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is GBX 2,018.75 ($25.51).

Separately, Berenberg Bank lifted their price objective on shares of Hikma Pharmaceuticals from GBX 1,960 ($24.77) to GBX 2,000 ($25.27) and gave the company a “hold” rating in a research note on Monday, February 26th.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock opened at GBX 1,880.50 ($23.76) on Friday. Hikma Pharmaceuticals has a 1 year low of GBX 1,614.50 ($20.40) and a 1 year high of GBX 2,222 ($28.08). The company has a debt-to-equity ratio of 53.92, a quick ratio of 1.27 and a current ratio of 1.57. The firm has a market cap of £4.17 billion, a price-to-earnings ratio of 2,806.72, a PEG ratio of 2.38 and a beta of 0.45. The stock’s 50-day moving average is GBX 1,928.72 and its two-hundred day moving average is GBX 1,905.78.

Hikma Pharmaceuticals Increases Dividend

The business also recently declared a dividend, which will be paid on Friday, May 3rd. Stockholders of record on Thursday, March 21st will be given a dividend of $0.47 per share. This represents a dividend yield of 1.86%. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.25. The ex-dividend date of this dividend is Thursday, March 21st. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is presently 8,507.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded.